← Back to Screener
Sensei Biotherapeutics, Inc. Common Stock (SNSE)
Price$31.39
Favorite Metrics
Price vs S&P 500 (26W)162.03%
Price vs S&P 500 (4W)-12.88%
Market Capitalization$40.87M
All Metrics
Book Value / Share (Quarterly)$14.74
P/TBV (Annual)0.16x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-16.22
Price vs S&P 500 (YTD)181.62%
EPS (TTM)$-16.73
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-16.73
EPS (Annual)$-16.72
ROI (Annual)-112.92%
Cash / Share (Quarterly)$16.79
ROA (Last FY)-92.07%
EBITD / Share (TTM)$-17.57
ROE (5Y Avg)-63.32%
Cash Flow / Share (Annual)$-16.22
P/B Ratio2.20x
P/B Ratio (Quarterly)0.72x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-28.13x
ROA (TTM)-69.97%
EPS Incl Extra (Annual)$-16.72
Current Ratio (Annual)5.06x
Quick Ratio (Quarterly)5.00x
3-Month Avg Trading Volume0.23M
52-Week Price Return232.86%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.84
52-Week High$36.76
EPS Excl Extra (Annual)$-16.72
CapEx CAGR (5Y)-57.90%
26-Week Price Return170.78%
Quick Ratio (Annual)5.00x
13-Week Price Return154.51%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.06x
Enterprise Value$32.277
Revenue / Employee (Annual)$0
Cash / Share (Annual)$16.79
3-Month Return Std Dev385.13%
Net Income / Employee (TTM)$-2
ROE (Last FY)-113.41%
EPS Basic Excl Extra (Annual)$-16.72
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-16.73
ROI (TTM)-82.58%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.36
Price vs S&P 500 (52W)197.77%
Year-to-Date Return185.75%
5-Day Price Return1.13%
EPS Normalized (Annual)$-16.72
ROA (5Y Avg)-53.89%
Month-to-Date Return-3.27%
Cash Flow / Share (TTM)$-1.28
EBITD / Share (Annual)$-17.57
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-62.33%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-16.73
P/TBV (Quarterly)0.23x
P/B Ratio (Annual)0.72x
Book Value / Share (Annual)$14.74
Price vs S&P 500 (13W)151.64%
Beta-0.09x
Revenue / Share (TTM)$0.00
ROE (TTM)-83.59%
52-Week Low$5.25
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SNSESensei Biotherapeutics, Inc. Common Stock | — | — | — | — | $31.39 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Sensei Biotherapeutics is an immuno-oncology company developing next-generation cancer therapeutics through its TMAb (Tumor Microenvironment Activated Biologics) platform, which targets immunosuppressive and immunostimulatory signals within tumors. The company has four clinical-stage candidates in development: SNS-101 (VISTA), SNS-102 (VSIG4), SNS-103 (ENTPDase/CD39), and SNS-201 (VISTAxCD28). This targeted approach aims to improve outcomes for cancer patients by modulating the tumor microenvironment.